San Francisco Chronicle

Drugmakers pressed for records on opioid sales

- Kevin Freking is an Associated Press writer. By Kevin Freking

WASHINGTON — A Democratic senator is seeking marketing informatio­n, sales records and studies from manufactur­ers of the top-selling opioid products in the United States to determine whether drugmakers have contribute­d to an overuse of the pain killers.

Sen. Claire McCaskill of Missouri said sales of prescripti­on opioids have quadrupled since 1999, taking a financial toll on the government and a deadly toll on thousands of consumers.

At the same time, President Trump convened an emotional roundtable Wednesday attended by New Jersey Gov. Chris Christie, members of his Cabinet, law enforcemen­t chiefs and recovering addicts. It was the first public event tied to the launch of a new addiction commission that Trump asked Christie, a longtime friend and formal rival, to chair.

McCaskill said previous government and media reports show an industry not focused on preventing abuse but on fostering addiction. She is investigat­ing whether such practices continue today.

Some of the records she is asking for from the five companies include the sales rep expenses for entertaini­ng physicians, payments made to health care advocacy groups, as well as marketing and business plans.

“We have an obligation to everyone devastated by this epidemic to find answers,” McCaskill said in a prepared statement. “All of this didn’t happen overnight. It happened one prescripti­on and marketing program at a time.”

More than 52,000 people died of drug overdoses in 2015, and roughly two-thirds of them had used prescripti­on opioids like OxyContin or Vicodin or illegal drugs like heroin, according to the Centers for Disease Control and Prevention. Those overdoses have jumped 33 percent in the past five years alone, with some states reporting the death toll had doubled or more.

In September, the Associated Press and Center for Public Integrity published an investigat­ion outlining how makers of prescripti­on painkiller­s have adopted a 50-state strategy that includes hundreds of lobbyists and millions in campaign contributi­ons to help kill or weaken measures aimed at stemming the tide of prescripti­on opioids.

The industry and its allies spent more than $880 million nationwide on lobbying and campaign contributi­ons from 2006 through 2015 — more than 200 times what those advocating for stricter policies spent and eight times more than the influentia­l gun lobby recorded for similar activities during that same period, the investigat­ion found.

McCaskill is the ranking Democratic lawmaker on the Senate Committee on Homeland Security and Government­al Affairs. The Republican chairman, Sen. Ron Johnson of Wisconsin, did not sign the letter seeking the informatio­n from the drug manufactur­ers, and an aide said Republican­s weren’t given time to join the investigat­ion.

Brittni Palke, spokeswoma­n for the committee, said McCaskill waited until the last minute to notify Johnson of the probe. She said Johnson was disappoint­ed by McCaskill’s decision to “get headlines instead of results.”

“Contrary to the committee’s long-standing bipartisan traditions, Sen. McCaskill chose to make her requests unilateral­ly despite widespread interest in coming together to address the root causes of America’s opioid addiction,” Palke said.

 ?? J. Scott Applewhite / Associated Press ?? Sen. Claire McCaskill, D-Mo., says the drug industry is not focused on preventing abuse but on fostering addiction.
J. Scott Applewhite / Associated Press Sen. Claire McCaskill, D-Mo., says the drug industry is not focused on preventing abuse but on fostering addiction.

Newspapers in English

Newspapers from United States